Overview

Disulfiram in Recurrent Glioblastoma

Status:
Completed
Trial end date:
2021-01-15
Target enrollment:
Participant gender:
Summary
Disulfiram (Antabuse®) is a well-tolerated, cheap, generic drug that has been in use since the 1950s to treat alcoholism. There is now an increasing amount of independent preclinical data to support disulfiram as an anticancer agent. The potency of disulfiram as an anticancer agent seems strengthened by copper. The investigators aim is to investigate disulfiram and copper-supplement as add-on treatment in glioblastoma patients with recurrence receiving alkylating chemotherapy.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sahlgrenska University Hospital, Sweden
Collaborators:
Karolinska University Hospital
Lund University Hospital
Region Örebro County
Ryhov County Hospital
St. Olavs Hospital
University Hospital, Linkoeping
Uppsala University Hospital
Treatments:
Alkylating Agents
Copper
Disulfiram
Lomustine
Temozolomide